– Frank Gleeson, Satellos CEO, to participate
in a panel discussion titled "Research Row: PPMD Moving the Needle"
on June 29, 2024 –
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX:
MSCL, OTCQB: MSCLF), a public biotech company developing new small
molecule therapeutic approaches to improve the treatment of muscle
diseases and disorders, today announced that Frank Gleeson,
Satellos CEO, will join leading members of the Duchenne medical and
scientific community during a panel discussion at PPMD's 30th
Annual Conference being held from June 27–29, 2024 in Orlando,
Florida.
"For three decades, PPMD has demonstrated unwavering dedication
to groundbreaking research and treatments, nurturing a supportive
community," said Frank Gleeson, Co-founder and CEO of Satellos. "I
am immensely honoured to be invited to participate in this
prestigious event. More importantly, we are proud to have been a
recipient of a programmatic investment by PPMD in 2021 that has
supported our crucial work towards developing an oral drug
candidate that might offer an improved treatment option for all
Duchenne patients, regardless of genetic mutation."
Gleeson added, "PPMD and its indomitable founder and CEO, Pat
Furlong, have been committed to exploring and supporting improved
treatments, quality of life and long-term outlook for all
individuals affected by Duchenne—we are truly gratified to partner
with PPMD and I look forward to achieving remarkable outcomes
together."
“I am so proud of our PPMD community—people living with
Duchenne, families, caregivers, healthcare providers, our employees
and volunteers, industry partners and donors—all of whom have
played an important role in shaping and advancing the treatment of
Duchenne,” said Pat Furlong, PPMD’s Founding President and CEO. "As
we endeavor to improve treatments, we hope to inspire excellence in
the biopharma industry so that, with innovative approaches to
treating Duchenne, we can achieve our mission to end this disease.
I am encouraged by the promising work that has been done by
Satellos to create and develop a drug candidate designed to address
an unmet medical need in Duchenne by restoring the body’s own
muscle stem cells’ ability to repair and regenerate muscles.”
Satellos intends to submit a regulatory package in July to
initiate a first-in-human Phase 1 clinical trial, in the third
quarter of 2024, that will evaluate the safety and pharmacokinetic
properties of SAT-3247 in healthy human volunteers.
About SAT-3247 SAT-3247 is designed as a once-daily, oral
small molecule drug that targets the root cause of muscle loss in
degenerative diseases, initially in Duchenne. SAT-3247 presents a
novel mechanism of action to restore impaired muscle regeneration
caused by the absence of functional dystrophin.
About Duchenne Muscular Dystrophy Duchenne muscular
dystrophy is an inherited disease caused by mutations in the
dystrophin gene that no longer allow the dystrophin protein to
function properly. Consequently, as discovered by Satellos, muscle
repair and regeneration are impaired. Satellos designed SAT-3247 to
restore the process of muscle repair and regeneration by regulating
a dystrophin-independent pathway with the goal of increasing muscle
function. SAT-3247 is intended to work as a standalone therapeutic
without regard to a patient’s genetic mutation or ambulatory
status. This approach has the potential to complement approaches
designed to restore dystrophin production.
About Satellos Bioscience Inc. Satellos is a publicly
traded biotechnology company dedicated to developing life-improving
medicines to treat degenerative muscle diseases. Satellos has
incorporated breakthrough research in muscle stem cell polarity
into a proprietary discovery platform, called MyoReGenX™, to
identify degenerative muscle diseases where deficits in this
process affect muscle regeneration and are amenable to therapeutic
intervention. With this platform, Satellos is building a pipeline
of novel therapeutics to correct muscle stem cell polarity and
promote the body’s innate muscle repair and regeneration process.
The Company’s lead program is an oral, small molecule drug
candidate in development as a potential disease-modifying treatment
for Duchenne muscular dystrophy. Satellos is headquartered in
Toronto, Ontario. For more information, visit www.satellos.com.
Notice on Forward-Looking Statements This press release
includes forward-looking information or forward-looking statements
within the meaning of applicable securities laws regarding Satellos
and its business, which may include, but are not limited to,
statements regarding the anticipated benefits to patients from an
oral small molecule treatment for Duchenne; the ability to achieve
remarkable outcomes; the advancement of our lead drug candidate
into clinical trials; the pharmacodynamic properties and
mechanism-of-action of our lead drug candidate; the general
benefits of modulating stem cell polarity by administering small
molecule drugs; its/their prospective impact on Duchenne patients;
that our approach has the potential to complement approaches
designed to restore dystrophin production; the utility of
regenerating muscle by modulating polarity; and Satellos’
technologies and drug development plans. All statements that are,
or information which is, not historical facts, including without
limitation, statements regarding future estimates, plans, programs,
forecasts, projections, objectives, assumptions, expectations or
beliefs of future performance, occurrences or developments, are
“forward-looking information or statements.” Often but not always,
forward-looking information or statements can be identified by the
use of words such as “shall”, “intends”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”,
“prospective” , “assert” or any variations (including negative or
plural variations) of such words and phrases, or state that certain
actions, events or results “may”, “might”, “can”, “could”, “would”
or “will” be taken, occur, lead to, result in, or, be achieved.
Such statements are based on the current expectations and views of
future events of the management of the Company. They are based on
assumptions and subject to risks and uncertainties. Although
management believes that the assumptions underlying these
statements are reasonable, they may prove to be incorrect. The
forward-looking events and circumstances discussed in this release,
may not occur and could differ materially as a result of known and
unknown risk factors and uncertainties affecting the Company,
including, without limitation, risks relating to the pharmaceutical
and bioscience industry (including the risks associated with
preclinical and clinical trials and regulatory approvals), and the
research and development of therapeutics, the results of
preclinical and clinical trials, general market conditions and
equity markets, economic factors and management’s ability to manage
and to operate the business of the Company generally, including
inflation and the costs of operating a biopharma business, and
those risks listed in the “Risk Factors” section of Satellos’
Annual Information Form dated March 26, 2024 (which is located on
Satellos’ profile at www.sedarplus.ca). Although Satellos has
attempted to identify important factors that could cause actual
actions, events or results to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events or results to differ from those
anticipated, estimated or intended. Accordingly, readers should not
place undue reliance on any forward-looking statements or
information. No forward- looking statement can be guaranteed.
Except as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and
Satellos does not undertake any obligation to publicly update or
revise any forward-looking statement, whether resulting from new
information, future events, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627838990/en/
Investors: Liz Williams, ir@satellos.com Business Development:
Ryan Mitchell, Ph.D., bd@satellos.com Media: Jessica Yingling,
Ph.D., jessica@litldog.com, +1.858.344.8091
Satellos Bioscience (TSX:MSCL)
Historical Stock Chart
From Oct 2024 to Nov 2024
Satellos Bioscience (TSX:MSCL)
Historical Stock Chart
From Nov 2023 to Nov 2024
